Hi Thaliat,
That's because that's what a Phase I study is always about. There can be secondary efficacy endpoints/notes. but Phase I studies are always about safety.
Also, importantly, that's the name and official title of the study.
Check out the link below for a study and have a look at the Primary, Secondary and Other Outcome measures.
Primary are always safety and dosage in phase I
https://classic.clinicaltrials.gov/ct2/show/NCT05346484
Understanding Cancer, page-7
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.001(1.41%) |
Mkt cap ! $527.0M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.6¢ | 7.1¢ | $2.390M | 32.54M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1642723 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 68400 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.3¢ |
Change
0.001 ( 2.24 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.6¢ | 7.1¢ | 9279379 | ||
| Last updated 15.58pm 17/05/2024 ? | |||||
| IMU (ASX) Chart |